Company / SG&A Expense
Jazz Pharmaceuticals SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.8B
FY2025
5-year range
$736.9M / $1.8B
FY2021-FY2025
Trend
+30.6%
vs FY2024
Sector context
#15 of 213
Health Care
What the data says
Among 213 Health Care companies, Jazz Pharmaceuticals is in the bottom 7% for sg&a expense. SG&A Expense has increased for 7 consecutive years, from $503M in FY2018 to $1.8B in FY2025.
Based on SEC 10-K filings.
$1.8B in FY2025 with a 5-year CAGR of +21.5%. Top quartile in the Health Care sector.
Increased from $1.3B to $1.8B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +28.4%
- 5-Year CAGR
- +21.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 213This company $1.8B Sector average $722.3M
▼
+150.5% above sector average
Key checks
Key Insights
- Jazz Pharmaceuticals's sg&a expense has grown for 7 consecutive years.
- 5-year CAGR of +21.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 30.6% year-over-year.
- Ranks #15 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8B | +30.6% |
| FY2024 | $1.4B | +3.1% |
| FY2023 | $1.3B | +57.2% |
| FY2022 | $854.2M | +15.9% |
| FY2021 | $736.9M | +7.8% |
| FY2020 | $683.5M | +25.6% |
| FY2019 | $544.2M | +8.2% |
| FY2018 | $502.9M | -7.6% |
| FY2017 | $544.2M | +34.0% |
| FY2016 | $406.1M | -9.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026